Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, Massachusetts-based drug developer’s lead product candidate is being studied in severe asthma and chronic obstructive pulmonary disease (COPD), according to Generate’s filing Wednesday with the US Securities and Exchange Commission.

Original title: “Flagship-Backed Drug Firm Generate Biomedicines Files for US IPO - Bloomberg”

Drug developer Eikon ‍Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initial public offering, selling about 21.2 million shares priced at $18 apiece. The offering comes as IPO activity shows signs of picking up in 2026, following a government shutdown in October of the previous year that forced many companies to delay their listing plans. Biotech offerings are also seeing a resurgence early this year, with drug developers including SpyGlass Pharma and AgomAb Therapeutics filing for U.S. BusinesscategoryCarrefour confident for 2026, Cora & Match acquisition weighs on 2025 operating profit

Original title: “Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO | Reuters”

The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year. Developing an Array of Diverse Vaccine Platforms Webinar - on demand • Provided by BioPharma Dive's studioID; Sponsored content by Novavax in partnership with studioID · Get the free daily newsletter read by industry experts ... MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Exp… ... Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate) ... According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year. Eikon’s pricing comes during the busiest week for biotech IPO activity since early last year, according to BioPharma Dive data. Veradermics, a hair loss treatment developer, raised $256 million in an IPO on Tuesday. Inflammatory disease drugmaker Agomab Therapeutics and eye-focused biotech Spyglass Pharma could follow on Thursday, according to the Nasdaq stock exchange. The cancer and neurological drugmaker is the third biotechnology company to price an IPO in 2026. Published Feb. 4, 2026 ... Eikon Therapeutics is one of four biotechnology companies aiming to go public this week. Getty Images · Eikon Therapeutics, a star-studded biotechnology startup that raised more than $1 billion in venture funding, said Wednesday it has secured $381 million more through an initial public offering. Since peaking in 2021, biotech IPOs have been much harder to pull off. Data show about two dozen in each of the following three years and only 11 in 2025. Industry watchers have suggested the pace of new stock offerings could pick up in 2026, though, fueled by the positive performance of last year’s small crop and pitches from more seasoned, IPO-ready companies.

Original title: “Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings | BioPharma Dive”

In 2025, Applied Clinical Trials caught up with Worldwide’s Derek Ansel, vice president, therapeutic strategy lead, rare disease. Worldwide Clinical Trials’ acquisition of Catalyst Clinical Research strengthens oncology expertise and functional service provider capabilities, expanding global trial delivery and flexible resourcing models across early and late phase development. A lot of the rare diseases we treat today don't have the same symptoms. We don't see the same severity of symptoms in all patients, so when you go and create a clinical program to prove that your drug is efficacious or effective and safe, regulators really look for defining data.” · 1. Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research. Worldwide Clinical Trials has entered into a definitive agreement to acquire Catalyst Clinical Research, a specialized oncology-focused contract research organization (CRO), in a move aimed at strengthening oncology expertise, expanding functional service provider (FSP) offerings, and enhancing global trial delivery.1 Worldwide Clinical Trials' acquisition of Catalyst Clinical Research enhances oncology expertise and expands functional service provider offerings.

Original title: “Worldwide Clinical Trials to Acquire Catalyst Clinical Research, Expanding Oncology and FSP Capabilities | Applied Clinical Trials Online”

In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn's disease and ulcerative colitis.

Original title: “Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I”

Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.

Original title: “Novo’s Wegovy Pill Success Is ‘Good News’ for Orforglipron, Lilly Execs Say”

On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.

Original title: “AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas”

Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.

Original title: “Novo Goes ‘All In’ on Wegovy Pill but Analysts Worry It’s Not Enough”

Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.

Original title: “Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods”

After review, Amgen is certain that Tavneos is effective and has a favorable benefit-risk profile. The company informed the FDA on January 28 that they would not pull the drug.

Original title: “Amgen Will Not Heed FDA Request To Withdraw Rare Disease Drug Tavneos”

Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.

Original title: “GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity”

Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.

Original title: “Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4”

Novartis will still be on the lookout for early-stage deals under $2 billion, and later-stage agreements around a product that could reach the market within five years, CEO Vas Narasimhan said Wednesday.

Original title: “Novartis Sticks With M&A Strategy of Building Early Pipeline, Searching for Near-Launches”

Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed execs for more details; Merck and Roche also released Q4 and full year earnings, with Eli Lilly, Novo Nordisk and others reporting Wednesday; REGENXBIO hits a regulatory snag ahead of its upcoming PDUFA; more.

Original title: “Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs”

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors. While supportive of Amylyx’s acquisition of a GLP-1 drug, analysts say the company’s future hinges on key upcoming readouts from multiple products in its pipeline. ... Of all the companies on this list, Invivyd most directly benefited from the influx of pandemic cash, with its $336 million series C in April 2021 promising to fund the development of ADG20, the biotech’s lead candidate being tested for the prevention and treatment of COVID-19. Verve entered the industry with a mission to harness gene and base editing for cardiovascular diseases. While the Massachusetts-based biotech no doubt benefited from the pandemic-induced influx of money, it remained true to its identity, even as many peers pivoted to addressing the virus. In the months leading up to the IPO, Verve worked on its editing technology for lowering LDL cholesterol and a preclinical program for atherosclerotic cardiovascular disease (ASCVD). In late 2020, Bayer led the biotech’s $65 million series A round, while Moderna in 2021 partnered with the startup to advance in vivo therapies for genetic diseases. Both Bayer and Moderna then co-led Metagenomi’s series B round in 2023, bringing in $275 million for the biotech. But the public markets have been hard on Metagenomi, which still does not have a candidate in the clinic. The company’s stock has fallen some 85% since its February 2024 debut. The company’s shares were trading at $1.60 apiece as of Dec. 2, nearly one-tenth of its $15-per-share IPO price. Caribou also pivoted from oncology to autoimmune diseases in September 2024, after its lead asset CB-010 won the FDA’s fast track designation for systemic lupus erythematosus. But immunology would not work out for Caribou either, forcing the biotech in April this year to return to its oncology origins—and lay off 32% in the process.

Original title: “2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now? - BioSpace”

NanoSyrinx has appointed Thomas Farrell as CEO and Director

Original title: “Thomas Farrell”

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like MPS II moving into the spotlight.

Original title: “From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era”

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.

Original title: “2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?”

Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.Generate Biomedicines states that its AI-enabled Generate Platform is a tight and ... Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.Generate Biomedicines states that its AI-enabled Generate Platform is a tight and fully-integrate...

Original title: “GENB IPO News - Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO”

Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for this year.

Original title: “Novo Slides 14% as Early Q4 Results Predict Sales Decline for 2026”